Stephan Moll, MD writes… A new consensus guidance on management of venous thromboembolism (VTE) - link here – was published today, Jan 18th, 2016, in the Journal of Thrombosis and Thrombolysis. The publication contains 13 chapters on various aspects of VTE Read the rest of this entry »
The ACCP Chest Guidelines have been the main guide over the last more than 2 decades for evidence-based recommendations on best management of anticoagulants for various indications, including DVT and PE. The 10th edition of the chapter on DVT and PE management was published today (link to the guideline here). Read the rest of this entry »
Stephan Moll, MD writes… Can patients on anticoagulants safely scuba dive? In general: “Yes”. Many people who take anticoagulants are able to safely dive. However, there are a few things to consider: Read the rest of this entry »
Stephan Moll, MD writes… A plain language summary for patients and interested public about homocysteine and the MTHFR mutations and their relevance in respect to thrombosis was published today in the journal Circulation (link here).
Reference: Moll S, Varga EA. Homocysteine and MTHFR Mutations. Circulation. 2015;132:e6-e.
Stephan Moll, MD writes: Interesting and relevant publication today in the New England Journal of Medicine (NEJM) Read the rest of this entry »
Stephan Moll, MD writes… A publication in the New England Journal of Medicine today reports on the use of the Pradaxa® (Dabigatran) antidote Idarucizumab in patients on Pradaxa® who present with major bleeding or require urgent surgery [ref 1]. Read the rest of this entry »
Stephan Moll, MD writes… An information article on various aspects of thrombophilia, written for patients and family members, was published today – available here - as a Vascular Disease Patient Information Page in the journal Vascular Medicine. It addresses (a) in which patient with venous thromboembolism to consider thrombophilia testing, (b) what tests might be appropriate to do, (c) how the test results might influence length of anticoagulation therapy (d), what contraceptives are safe to use in women with a history of DVT or PE or thrombophilia, and (e) in which family members to consider thrombophilia testing. This article can be used as an education handout for patients in clinic or the hospital who have DVT, PE, venous thrombosis in unusual locations, or an established thrombophilia.
Last updated: April 1st, 2015
Stephan Moll, MD writes... The annual American Society of Hematology (ASH) meeting took place in Dec 2014 in San Francisco. A summary of the clinically relevant thrombosis and anticoagulation presentation and abstracts is presented here (Top 10 ASH Highlights).
Disclosure: I have been a consultant to Portola, Daiichi, Janssen, and Boehringer-Ingelheim.
Last updated: Jan 27th, 2015
Stephan Moll, MD writes…. Today (Jan 8th, 2015) the FDA approved yet another new oral anticoagulant, Savaysa (edoxaban), for the treatment of DVT and PE, as well as for atrial fibrillation. The FDA press release is here (link). Savaysa is the 4th of the NOACS now approved for VTE treatment. This table summarizes the differences, advantages and disadvantages comparing the 4 drugs. The detailed drug package insert with dosing information is here (link). Read the rest of this entry »
Stephan Moll, MD writes (Dec 17, 2014)… The American Society of Hematology (ASH) published last week as part of its Choosing Wisely® campaign two things that physicians dealing with DVT, PE and anticoagulants should avoid [ref 1]. Read the rest of this entry »